Literature DB >> 10600025

Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies.

Y Komada1, H Inaba, Q S Li, E Azuma, Y W Zhou, H Yamamoto, M Sakurai.   

Abstract

Fas (CD95) is a cell surface glycoprotein that mediates apoptotic cell death when cross-linked with agonistic anti-Fas monoclonal antibodies (MAbs) or the endogenous Fas ligand. In this study, we investigated the in vitro biological properties of a panel of anti-human Fas MAbs. We found that five anti-Fas MAbs of IgG1 subclass (B.E28, B.G30, B.L25, DX2, and B.G34) induced marked apoptotic cell death in Fas-expressing leukemia cells, although this killing was delayed when compared to the cytolytic effect mediated by the prototypic anti-Fas MAb of IgM subclass (clone CH-11). On the other hand, four clones (ZB4, B.G27, B.D29, and B.K14) efficiently blocked apoptotic cell death induced by the CH-11 MAb or Fas ligand. The ability of these MAbs to inhibit cell death appeared to correlate with their relative affinity for the Fas molecule. Furthermore, different clones recognized the same epitope and elicited different effects (induction or inhibition of cell killing); conversely, different clones elicited the same effect but recognized different epitopes. These results suggest that the different biological effects of anti-Fas MAbs would not be mediated in an epitope-restricted manner. The relative binding affinity might correlate to some extent with the biological properties of the MAb.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600025     DOI: 10.1089/hyb.1999.18.391

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

Review 1.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 2.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

3.  A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency.

Authors:  M Chodorge; S Züger; C Stirnimann; C Briand; L Jermutus; M G Grütter; R R Minter
Journal:  Cell Death Differ       Date:  2012-01-20       Impact factor: 15.828

4.  Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene - methyltetrazine reactions.

Authors:  Michiro Muraki; Kiyonori Hirota
Journal:  BMC Biotechnol       Date:  2017-07-03       Impact factor: 2.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.